Teriparatide

Areas of active research — not promised effects

Each tag links to other compounds with research into that goal. Research use only: these are areas of study, not human-use claims.

Related by research scope · open each to compare

Available by prescription under brand names Forteo (Eli Lilly) and Bonsity (Teva/biosimilar) for osteoporosis treatment and glucocorticoid-induced osteoporosis. Requires a valid prescription and licensed prescriber. As an FDA-approved product, teriparatide is outside the FDA-19 compounding Category 1/Category 2 framework — it is not a bulk compounding substance, and the fda19 flag is false.

Transparent blend · bci-1.0 · never paid-placement

Primary name

Teriparatide

Origin

Synthetic 34-amino acid peptide corresponding to the biologically active N-terminal fragment of human parathyroid hormone. Produced by recombinant DNA technology in Escherichia coli and identical in sequence to endogenous PTH(1-34). First approved by the FDA in November 2002 under the brand name Forteo (Eli Lilly); biosimilar Bonsity (Teva/Peptide YY) approved October 2019.

Registry IDs

PubChem CID

16133850

CAS

52232-67-4

InChIKey

OGBMKVWORPGQRR-UMXFMPSGSA-N

ChEMBL

CHEMBL525610

Molecular formula

C181H291N55O51S2

Molar mass

4118 g/mol

Monoisotopic

4115.1309424 Da

InChIKey

OGBMKVWORPGQRR-UMXFMPSGSA-N

Appearance

Clear, colorless solution for injection (commercial form); lyophilized white powder (research-grade)

Solubility

Freely soluble in aqueous solution at physiological pH; commercial product suppl…

Sequence not available in current seed.

Stability: Susceptible to thermal degradation and agitation; avoid freezing, direct sunlight, and vigorous shaking. The peptide is most stable in buffered aqueous solution

Vial sizes

null mg

Purity grades

pharmaceutical grade (commercial)

Salt forms

Free base (primary)

• GHS hazard class on file
• PPE & spill response
• Disposal guidance
• Not-for-human-consumption posture

How much research exists, and of what maturity — never a verdict on whether it works.

Mechanism of action

• Teriparatide binds and activates the parathyroid hormone type 1 receptor (PTH1R), a class B G-protein-coupled receptor expressed on osteoblasts and osteocytes
• When administered as brief daily pulses (as opposed to continuous PTH elevation in hyperparathyroidism), PTH1R activation preferentially drives the cAMP/PKA/CREB signaling axis, promoting osteoblast differentiation, proliferation, and survival while reducing osteoblast apoptosis
• This intermittent signaling also suppresses sclerostin, thereby disinhibiting the Wnt/β-catenin pathway and further amplifying bone formation at trabecular, endocortical, and periosteal surfaces
• The net result is an anabolic skeletal effect — new bone matrix synthesis and mineralization — that distinguishes teriparatide from antiresorptive agents

Pharmacokinetics (ADME)

Half-life

approximately 1 hour (subcutaneous); 5 minutes (intravenous)

Clearance

~62 L/hr in women, ~94 L/hr in men; exceeds hepatic plasma flow, indicating hepatic plus extra-hepatic proteolytic clearance; renal excretion of fragments

PK–PD note: Following a 20 mcg subcutaneous dose, Cmax is reached at approximately 30 minutes; absolute bioavailability is ~95%. Total duration of peptide exposure is approximately 4 hours. Volume of distribution…

Reading the evidence

• Evidence quality and gaps vary by application — see the cited grades above.
• Indexed-article counts span all evidence tiers, not only completed human trials.
• No first-party human-dosing, efficacy, or benefit claims are made here.

Key reviews & evidence-gap sources

• Arthur Vithran DT et al. Teriparatide in postmenopausal osteoporosis: efficacy and safety compared to other treatments — systematic review and meta-analysis. EFORT Open Rev. 2024;9(9):845-861. — Anchoring systematic review/meta-analysis of RCTs 2000-Jan 2023
• Trevisani VF et al. Teriparatide (rhPTH 1-34) in postmenopausal women with osteoporosis: systematic review. Sao Paulo Med J. 2008;126(5):279-284. — Cochrane-methodology systematic review
• StatPearls — Teriparatide (Vall H, Patel P, Parmar M; updated Feb 2024) — Peer-reviewed reference covering mechanism, indications, FDA approval history

5 registered trials — 0 currently recruiting.

—
NCT01155245
Teriparatide (PTH) and Bone Strength in Postmenopausal Women

ACTIVE_NOT_RECRUITING

—
NCT05366621
Post-fracture Medication and Mortality

COMPLETED

Phase 3
NCT00542984
Comparison Medications in the Treatment of Postmenopausal Women With Osteoporosis

COMPLETED

—
NCT01155232
Effects of Teriparatide (PTH) on Bone in Men and Women With Osteoporosis

ACTIVE_NOT_RECRUITING

Phase 2
NCT04473989
Weekly Use of Teriparatide to Accelerate Healing of Distal Radius Fracture

UNKNOWN

Summary (literature)

Per the FDA-approved prescribing information (Forteo/Bonsity label, updated 2020 and 2024), the most commonly reported adverse effects include nausea, headache, dizziness, leg cramps, and arthralgia. Orthostatic hypotension may occur within 4 hours of dosing; patients should sit …

WADA status

PTH and its analogs fall under WADA S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), which is prohibited at all times (in- and out-of-com…

Dominant research route: SC

Approved/labelled route; PK characterized in postmenopausal women (n=360, Fracture Prevention Trial) and healthy/renally-impaired volunteers

Bioavailability: Absolute bioavailability approximately 95% (pooled 20/40/80 mcg SC doses); Cmax within ~30 min; apparent serum half-life ~1 h (reflects absorption from injection site, not true elimination); total peptide exposure ~4 h

Dominant clinical and labelled route; administered into thigh or abdominal wall. SC half-life longer than IV due to absorption-limited kinetics.

PK reference route in humans (used to derive true elimination half-life for comparison with SC)

Bioavailability: True elimination half-life ~5 min when administered by IV injection (vs ~1 h apparent half-life after SC); IV used as comparator for absolute bioavailability determination

IV is not a therapeutic route; cited only as the reference infusion for bioavailability/elimination characterization in label PK studies.

Preclinical/in-vitro only: GI proteolysis studies in rat intestinal mucosa; nanoparticle/nanoemulsion/MOF oral formulation research (no approved oral teriparatide)

Bioavailability: Not orally bioavailable as native peptide; ~50% degraded within 3 h in rat small-intestinal mucosa (aminopeptidase N implicated). Encapsulated/nanoemulsion formulations studied to protect peptide and enable absorption in animal models.

Oral-stability (not oral-absorption) finding: teriparatide is rapidly cleaved by GI proteolytic enzymes; oral delivery research focuses on protection from enzymatic degradation rather than intrinsic oral absorption.

Animal & human figures are kept visibly separate so studied animal doses are never misread as human guidance.

Sorted A–Z by vendor — never by price

Teriparatide lost US exclusivity with follow-on biologic Bonsity (Oct 2019) and subsequent generics/biosimilars; research-chem pricing has been stable with periodic discounting. No clear directional data for RUO powder market.

Researched storefront prices, bucketed

p25 $17.15 · median $62.11 · p75 $161.00 · 6 researched vendors

Legit, COA-backed band: $14.30–$201.00/mg.

Value rule: don't just buy the cheapest — a price under $3/mg is a red flag. Pair price with COA and independent-test grade.

Estimated cost of research (10 mg)

Vial (best researched price)

$15

Bacteriostatic water (generic estimate)

$6

Syringes / supplies (generic estimate)

$12

What each test proves — general guidance, plus this compound's researched purity data

Independent labs cited for this compound

The only teriparatide-specific recall located is the 2011 Class 2 recall of Forteo starter kits (Triad alcohol prep pads, Bacillus cereus contamination) — the drug product itself was not recalled. No teriparatide drug-substance recalls, counterfeit-lot seizures, or criminal enforcement actions specific to teriparatide were found in FDA Enforcement Reports or Partnership for Safe Medicines records (counterfeit/illegal-compounding enforcement has overwhelmingly targeted GLP-1 agonists such as semaglutide/tirzepatide, not teriparatide).

Buyer red-flag checklist

• Fraudulent online pharmacies may attempt to sell illegal/counterfeit 'generic Forteo' (teriparatide) — FDA notes these may be counterfeit and potentially unsafe (source: Drugs.com generic availability page, citing FDA).
• Teriparatide is a PTH(1-34) peptide biologic; any non-FDA-approved 'research peptide' teriparatide sold outside the regulated drug supply chain carries unknown purity, sterility, and identity risk.
• The FDA Import Alert 66-80 'green list' targets GLP-1 receptor agonist APIs (semaglutide, tirzepatide, liraglutide, exenatide, dulaglutide) — it does NOT cover teriparatide; absence from this alert does not imply teriparatide APIs are unrestricted.

GMP vs research-grade: the chemistry (SPPS + HPLC + MS) is identical — the difference is the quality system.

Underdosing / mislabeling: No independent third-party lab test results (Janoshik, MZ Biolabs, Finnrick, or equivalent) for teriparatide were located. Teriparatide is an FDA-approved biologic drug (Forteo/Bonsity and generics) manufactured under GMP; it is not a common 'research peptide' sold through grey-market vendors that typically publish Janoshik COAs, so aggregate community underdosing data is not available.

• An RUO label is not an import exemption — CBP judges actual intended use.
• Lyophilized powder is ambient-stable in transit; temperature control needed for > 7-day transit.
• US-warehouse vendors dodge import scrutiny — they cost more but ship more reliably.

Every item dated & sourced

Teriparatide (PTH 1-34 analog) is not explicitly named on the WADA Prohibited List. WADA S2 covers peptide hormones, growth factors, and mimetics; athletes should verify status via GlobalDRO. No specific WADA prohibition for teriparatide was identified in available sources.

No granted patents identified in current seed. Composition-of-matter coverage is limited given the peptide's synthetic origin.

• IACUC / IRB research context
• RUO buyer responsibilities & documentation
• Veterinary / alternative-use where lawful
• Jurisdiction-aware "who may lawfully obtain"

What people discuss

Reported concerns — discussion, not established effects

Reading caveats

• Self-selection toward negative reporting on side-effect threads
• Cost barrier skews discourse toward insured/affluent users
• Historical black-box warning inflates osteosarcoma concern relative to current label
• Review-platform ratings bimodal: strong positives and strong negatives both over-represented

Manually researched from reddit, youtube— theme weights are research estimates, not live counts; aggregated & de-identified. No individual posts, quotes, or usernames are ever shown.

Relative research / market volume — populated once the activity stream is wired

Inline tooltips for lyophilized, RUO, EU/mg, SPPS, 503A and more.

Toggle plain-language ↔ scientific in the header.

• How to read a COA
• Free base vs acetate
• Understanding evidence grades

FDA-approved recombinant PTH(1-34) analog (Forteo/Bonsity) that stimulates bone formation for osteoporosis at high fracture risk. Approximately 3,918 articles are indexed (literature last scanned 2026-05-29). US regulatory status: FDA-approved prescription drug (Rx only). Research use only.

Emitted as JSON-LD: ChemicalSubstance · BreadcrumbList · FAQPage.

• Price-drop & back-in-stock alerts
• Regulatory-change email digest
• Print / share this datasheet